At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 205 enrolled
Drug / intervention
JUVÉDERM® VOLUMA® XC +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Evaluator-blinded, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing
In Brief
A Phase 3 clinical trial evaluating JUVÉDERM® VOLUMA® XC and No-treatment control for Temple Hollowing. Completed, enrolled 205 participants across 15 sites in 2 countries.
Detailed Summary
The objectives of this study are to evaluate the safety and effectiveness of Juvederm® Voluma® XC injectable gel in adult participants seeking correction of temple hollowing
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTemple Hollowing
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedJun 2020
Primary CompletionOct 2022
TodayJul 2026
First PostedJun 4, 2020
Enrollment StartMay 28, 2020
Primary CompletionOct 17, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.1 years ago
Interventions
JUVÉDERM® VOLUMA® XCdevice
JUVÉDERM® VOLUMA® XC injectable gel
No-treatment controlother
Participants received no treatment for 3 months during the Control Period.